Evidence map›Paper›PMID 27771945›Full record

ArticleBioconjugate chemistry2017

Binding and Uptake into Human Hepatocellular Carcinoma Cells of Peptide-Functionalized Gold Nanoparticles.

Satadru Jha, Federico Ramadori, Santina Quarta, Alessandra Biasiolo, Enrica Fabris, Paola Baldan, Gaetano Guarino, Mariagrazia Ruvoletto, Gianmarco Villano, Cristian Turato and 4 more

Open access · greenAbstract read
In one paragraph

Article in Bioconjugate chemistry, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 31 citations in OpenAlex.

  1. Review
  2. Nanoscale advances · 2025
    Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Peptide-Enabled Targeted Delivery Systems for Therapeutic Applications.Frontiers in bioengineering and biotechnology · 2021
    Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 3 institutions in 3 countries.

Satadru JhaDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Federico RamadoriDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Santina QuartaDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Alessandra BiasioloDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Enrica FabrisDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Paola BaldanDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Gaetano GuarinoDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Mariagrazia RuvolettoDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Gianmarco VillanoDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Cristian TuratoDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Angelo GattaDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Fabrizio MancinDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
Patrizia PontissoDipartimento di Medicina, Univeristà di Padova , via Giustiniani, 2, 35128 Padova, Italy.
Paolo ScriminDipartimento di Scienze Chimiche, Università di Padova , via Marzolo 1, 35131, Padova, Italy.
University of Padua · ITBiocon (Switzerland) · CHSikkim Manipal University · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the most daunting challenges of nanomedicine is the finding of appropriate targeting agents to deliver suitable payloads precisely to cells affected by malignancies. Even more complex is the ability to ensure that the nanosystems enter those cells. Here, we use 2 nm (metal core) gold nanoparticles to target human hepatocellular carcinoma (HepG2) cells stably transfected with the SERPINB3 (SB3) protein. The nanoparticles were coated with a 85:15 mixture of thiols featuring, respectively, a phosphoryl choline (to ensure water solubility and biocompatibility) and a 28-mer peptide corresponding to the amino acid sequence 21-47 of the hepatitis B virus-PreS1 protein (PreS1(21-47)). Conjugation of the peptide was performed via the maleimide-thiol reaction in methanol, allowing the use of a limited amount of the targeting molecule. This is an efficient procedure also in the perspective of selecting libraries of new targeting agents. The rationale behind the selection of the peptide is that SB3, which is undetectable in normal hepatocytes, is overexpressed in hepatocellular carcinoma and in hepatoblastoma and has been proposed as a target of the hepatitis B virus (HBV). For the latter, the key recognition element is the PreS1(21-47) peptide, which is a fragment of one of the proteins composing the viral envelope. The ability of the conjugated nanoparticles to bind the target protein SB3, expressed in liver cancer cells, was investigated by surface plasmon resonance analysis and in vitro via cellular uptake analysis followed by atomic absorption analysis of digested samples. The results showed that the PreS1(21-47) peptide is a suitable targeting agent for cells overexpressing the SB3 protein. Even more important is the evidence that the gold nanoparticles are internalized by the cells. The comparison between the surface plasmon resonance analysis and the cellular uptake studies suggests that the presentation of the protein on the cell surface is critical for efficient recognition.

Indexed as

Amino Acid SequenceCarcinoma, HepatocellularGoldHep G2 CellsHumansLiver NeoplasmsMetal NanoparticlesMicroscopy, Electron, TransmissionPeptidesProton Magnetic Resonance SpectroscopySpectroscopy, Fourier Transform InfraredGoldPeptides

Identifiers

PMID27771945
PMCPMC5247774
OpenAlexW2536753010

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.